Experimental drug fails to prove benefit in fatal infant brain diseases
NCT ID NCT03822013
First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 28 times
Summary
This study tested the drug miglustat in 30 infants with severe, often fatal forms of Sandhoff or Tay-Sachs disease. The goal was to see if the drug could reduce hospital stays, seizures, and feeding problems, and improve motor function and quality of life. The trial was terminated early, and results were not conclusive.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SUPPORTIVE CARE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kashan University Of Medical Sciences
Kāshān, Isfahan, Iran
-
Mashhad University Of Medical Sciences
Mashhad, Khorasan, Iran
-
Tehran University Of Medical Sciences
Tehran, Tehran Province, Iran
Conditions
Explore the condition pages connected to this study.